AU2013265295B2 - Compositions comprising short-acting benzodiazepines - Google Patents

Compositions comprising short-acting benzodiazepines Download PDF

Info

Publication number
AU2013265295B2
AU2013265295B2 AU2013265295A AU2013265295A AU2013265295B2 AU 2013265295 B2 AU2013265295 B2 AU 2013265295B2 AU 2013265295 A AU2013265295 A AU 2013265295A AU 2013265295 A AU2013265295 A AU 2013265295A AU 2013265295 B2 AU2013265295 B2 AU 2013265295B2
Authority
AU
Australia
Prior art keywords
composition
dextran
lyophilized
benzodiazepine
lactose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013265295A
Other languages
English (en)
Other versions
AU2013265295A1 (en
Inventor
Alan James Baillie
John Aitken Graham
Thomas Peacock
Kevin Richard WARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paion UK Ltd
Original Assignee
Paion UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013265295(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Paion UK Ltd filed Critical Paion UK Ltd
Publication of AU2013265295A1 publication Critical patent/AU2013265295A1/en
Application granted granted Critical
Publication of AU2013265295B2 publication Critical patent/AU2013265295B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2013265295A 2012-05-22 2013-05-22 Compositions comprising short-acting benzodiazepines Active AU2013265295B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12168968.1 2012-05-22
EP12168968 2012-05-22
PCT/EP2013/060543 WO2013174883A1 (en) 2012-05-22 2013-05-22 Compositions comprising short-acting benzodiazepines

Publications (2)

Publication Number Publication Date
AU2013265295A1 AU2013265295A1 (en) 2015-01-22
AU2013265295B2 true AU2013265295B2 (en) 2017-08-31

Family

ID=48669863

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013265295A Active AU2013265295B2 (en) 2012-05-22 2013-05-22 Compositions comprising short-acting benzodiazepines

Country Status (41)

Country Link
US (2) US20150148338A1 (enExample)
EP (1) EP2852389B1 (enExample)
JP (1) JP6313286B2 (enExample)
KR (1) KR102116737B1 (enExample)
CN (2) CN108578413A (enExample)
AP (1) AP2014008084A0 (enExample)
AR (1) AR092008A1 (enExample)
AU (1) AU2013265295B2 (enExample)
BR (1) BR112014029108B1 (enExample)
CA (1) CA2874247C (enExample)
CL (1) CL2014003171A1 (enExample)
CO (1) CO7151503A2 (enExample)
DK (1) DK2852389T3 (enExample)
EA (1) EA032119B1 (enExample)
EC (1) ECSP14032553A (enExample)
ES (1) ES2651389T3 (enExample)
FR (1) FR21C1043I2 (enExample)
GE (1) GEP20186852B (enExample)
HR (1) HRP20171872T1 (enExample)
HU (2) HUE037734T2 (enExample)
IL (1) IL235789B (enExample)
LT (2) LT2852389T (enExample)
LU (1) LUC00230I2 (enExample)
MA (1) MA37581B1 (enExample)
MX (1) MX368854B (enExample)
MY (1) MY185117A (enExample)
NL (1) NL301130I2 (enExample)
NO (2) NO2852389T3 (enExample)
NZ (1) NZ702063A (enExample)
PE (1) PE20150683A1 (enExample)
PH (1) PH12014502608B1 (enExample)
PL (1) PL2852389T4 (enExample)
PT (1) PT2852389T (enExample)
RS (1) RS56660B1 (enExample)
SG (1) SG11201407710VA (enExample)
SI (1) SI2852389T1 (enExample)
TN (1) TN2014000479A1 (enExample)
TW (1) TWI590826B (enExample)
UA (1) UA115063C2 (enExample)
WO (1) WO2013174883A1 (enExample)
ZA (1) ZA201408412B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2081921T1 (sl) 2006-07-10 2011-01-31 Paion Uk Ltd Soli benzodiazepina s kratkotrajnim učinkom ter njihove polimorfne oblike
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2015076340A1 (ja) * 2013-11-21 2015-05-28 小野薬品工業株式会社 全身麻酔および／または鎮静のための注射用組成物
JP6767881B2 (ja) 2014-02-10 2020-10-14 バイオルミック リミテッド 光合成生物の特徴の改善、及びそれに関する制御
MX380722B (es) 2014-03-14 2025-03-12 Biolumic Ltd Metodo para mejorar rendimiento y/o calidad de cultivos.
US9994578B2 (en) 2014-07-23 2018-06-12 Jiangsu Nhwaluokang Pharmceutical Research And Development Co., Ltd Benzodiazepine derivative and use thereof
AU2015318730B2 (en) 2014-09-17 2021-03-25 Biolumic Limited Method of seed treatments and resulting products
CN105726495B (zh) * 2014-12-12 2019-03-29 宜昌人福药业有限责任公司 一种注射用短效苯并二氮杂卓盐药物组合物及其制备方法
CN107198691A (zh) * 2016-03-17 2017-09-26 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
KR20180131617A (ko) * 2016-04-14 2018-12-10 파이온 유케이 리미티드 경구 흡입 및 비 벤조디아제핀
WO2017198224A1 (zh) * 2016-05-20 2017-11-23 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
WO2018037281A1 (en) 2016-08-22 2018-03-01 Biolumic Limited System, device and methods of seed treatment
CN108503644B (zh) 2016-12-09 2019-06-14 成都倍特药业有限公司 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途
WO2019002946A1 (en) 2017-06-29 2019-01-03 Biolumic Limited METHOD OF ENHANCING YIELD AND / OR CULTURE QUALITY
EP3714884A1 (en) 2019-03-27 2020-09-30 Paion UK Limited Medical uses for benzodiazepines with a particular eeg pattern
CN112209932B (zh) * 2019-07-12 2023-03-24 成都倍特药业股份有限公司 一种化合物氢溴酸盐的新固体形态及其制备方法和用途
ES2803099B2 (es) 2019-07-22 2021-11-08 Moehs Iberica Sl Procedimiento de obtención de besilato de remimazolam amorfo
CN114478535B (zh) * 2020-10-23 2024-02-09 成都苑东生物制药股份有限公司 一种苯磺酸瑞马唑仑ii晶型的制备方法
CN112462015B (zh) * 2020-11-18 2022-07-12 海南倍特药业有限公司 一种氢溴酸瑞马唑仑细菌内毒素的检测方法
CN114624351B (zh) * 2020-12-14 2024-04-09 宜昌人福药业有限责任公司 苯磺酸瑞马唑仑原料药中(r)-(-)-1-氨基-2-丙醇残留的分析方法
AU2023394304A1 (en) * 2022-12-16 2025-05-22 Lts Lohmann Therapie-Systeme Ag Oromucosal delivery system containing remimazolam
CN119101054A (zh) * 2023-06-09 2024-12-10 成都麻沸散医药科技有限公司 一种氮杂䓬类化合物及其组合物和应用
WO2025052259A1 (en) 2023-09-05 2025-03-13 Reena Patel Ready to use compositions of remimazolam

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007081A1 (en) * 2006-07-10 2008-01-17 Cenes Limited Short-acting benzodiazepine salts and their polymorphic forms
WO2008007071A1 (en) * 2006-07-10 2008-01-17 Cenes Limited Short-acting benzodiazepine salts and their polymorphic forms

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520877A (en) 1967-10-02 1970-07-21 Hoffmann La Roche 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
FI972865L (fi) 1995-01-06 1997-09-03 Hoffmann La Roche Hydroksimetyyli-imidatsodiatseptiinejä ja niiden esterit
AU4382896A (en) 1995-02-02 1996-08-21 F. Hoffmann-La Roche Ag Acetylimidazobenzodiazepines
JPH0971533A (ja) * 1995-06-30 1997-03-18 Takeda Chem Ind Ltd 凍結乾燥製剤
US7160880B1 (en) * 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1161949A1 (en) * 2000-06-09 2001-12-12 Warner-Lambert Company Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
WO2006088894A2 (en) * 2005-02-15 2006-08-24 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
GB0613692D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
EP3050885B1 (en) * 2009-11-05 2017-10-18 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
EP2450039A1 (en) * 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
CN102964349A (zh) * 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007081A1 (en) * 2006-07-10 2008-01-17 Cenes Limited Short-acting benzodiazepine salts and their polymorphic forms
WO2008007071A1 (en) * 2006-07-10 2008-01-17 Cenes Limited Short-acting benzodiazepine salts and their polymorphic forms

Also Published As

Publication number Publication date
MA37581B1 (fr) 2016-07-29
HUE037734T2 (hu) 2018-09-28
ECSP14032553A (es) 2018-11-30
EA201492160A1 (ru) 2015-10-30
TW201400119A (zh) 2014-01-01
DK2852389T3 (en) 2017-12-18
GEP20186852B (en) 2018-05-25
WO2013174883A1 (en) 2013-11-28
PE20150683A1 (es) 2015-06-03
AR092008A1 (es) 2015-03-18
CL2014003171A1 (es) 2015-06-19
JP6313286B2 (ja) 2018-04-18
CN108578413A (zh) 2018-09-28
NO2021041I1 (no) 2021-09-20
LT2852389T (lt) 2017-12-27
NO2852389T3 (enExample) 2018-03-17
KR102116737B1 (ko) 2020-05-29
AU2013265295A1 (en) 2015-01-22
CA2874247C (en) 2020-07-28
US20220040198A1 (en) 2022-02-10
NL301130I2 (nl) 2021-10-25
US20150148338A1 (en) 2015-05-28
BR112014029108A2 (pt) 2017-06-27
HUS2100040I1 (hu) 2021-10-28
JP2015517552A (ja) 2015-06-22
KR20150009601A (ko) 2015-01-26
MA20150233A1 (fr) 2015-07-31
BR112014029108B1 (pt) 2022-02-08
AP2014008084A0 (en) 2014-11-30
EP2852389A1 (en) 2015-04-01
HK1208164A1 (en) 2016-02-26
UA115063C2 (uk) 2017-09-11
FR21C1043I1 (enExample) 2021-11-19
PL2852389T4 (pl) 2022-02-21
ES2651389T3 (es) 2018-01-26
NL301130I1 (enExample) 2021-09-22
PL2852389T3 (pl) 2018-02-28
CN104968348A (zh) 2015-10-07
HRP20171872T1 (hr) 2018-02-23
LTC2852389I2 (enExample) 2024-11-25
EA032119B1 (ru) 2019-04-30
CA2874247A1 (en) 2013-11-28
EP2852389B1 (en) 2017-10-18
MY185117A (en) 2021-04-30
SI2852389T1 (en) 2018-02-28
SG11201407710VA (en) 2015-01-29
MX2014014225A (es) 2015-06-17
IL235789B (en) 2019-07-31
IL235789A0 (en) 2015-01-29
CO7151503A2 (es) 2014-12-29
PT2852389T (pt) 2017-12-13
TWI590826B (zh) 2017-07-11
PH12014502608A1 (en) 2015-01-21
MX368854B (es) 2019-10-18
LUC00230I2 (enExample) 2022-10-07
NZ702063A (en) 2016-11-25
LTPA2021521I1 (enExample) 2021-10-11
RS56660B1 (sr) 2018-03-30
FR21C1043I2 (fr) 2022-10-07
CN104968348B (zh) 2018-04-17
TN2014000479A1 (en) 2016-03-30
PH12014502608B1 (en) 2019-11-27
ZA201408412B (en) 2016-09-28

Similar Documents

Publication Publication Date Title
AU2013265295B2 (en) Compositions comprising short-acting benzodiazepines
JP5536753B2 (ja) ベンダムスチン塩酸塩の新規固体形態
JP5380549B2 (ja) ボリコナゾール含有の薬物製剤及びその調製方法
JP6869941B2 (ja) ある含有量のマイトマイシンｃを有する凍結乾燥医薬組成物を製造する方法
TW201632174A (zh) 使用晶體工程及茶胺酸溶解之平台藥物遞送系統
JP2016521731A (ja) 抗がん剤を含む安定な水溶性医薬組成物
JP6942182B2 (ja) カルグルミン酸を含有する非経口的薬剤配合物
Liu et al. Preparation, Characterization and Evaluation of Nintedanib Amorphous Solid Dispersions with Enhanced Oral Bioavailability
JP2022185009A (ja) 安定したアザシチジン含有医薬組成物の製造方法
CA2894935A1 (en) Novel crystalline forms of ceftaroline fosamil
EP1945182B1 (en) Formulations of tipifarnib for intravenous application
HK1208164B (en) Compositions comprising short-acting benzodiazepines
US9308174B2 (en) Lyophilized formulations of bendamustine hydrochloride
OA20108A (en) Compositions Comprising Short-Acting Benzodiazepines.
CN112175029A (zh) 抗真菌的大环多烯类新化合物
CN108289897B (zh) 一种瑞马唑仑的药物组合物
CN111100122A (zh) 左旋四氢帕马丁新化合物
BR112015005489B1 (pt) Composição farmacêutica para administração oral com dissolução e/ou absorção aperfeiçoadas

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)